ProShare Advisors
SMMT icon

ProShare Advisors’s Summit Therapeutics SMMT Stock Holding History

ProShare Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Sell
25,451
-9,235
-27% -$164K ﹤0.01% 1288
2026
Q1 		$658K Buy
34,686
+1,805
+5% +$29.2K ﹤0.01% 931
2025
Q4 		$575K Buy
32,881
+6,418
+24% +$121K ﹤0.01% 1060
2025
Q3 		$547K Sell
26,463
-1,269
-5% -$30.8K ﹤0.01% 1057
2025
Q2 		$590K Sell
27,732
-25,455
-48% -$580K ﹤0.01% 1036
2025
Q1 		$1.03M Sell
53,187
-7,643
-13% -$153K ﹤0.01% 804
2024
Q4 		$1.09M Buy
60,830
+1,474
+2% +$28.6K ﹤0.01% 875
2024
Q3 		$1.3M Buy
59,356
+499
+0.8% +$6.98K ﹤0.01% 741
2024
Q2 		$459K Sell
58,857
-11,138
-16% -$60.2K ﹤0.01% 1029
2024
Q1 		$290K Buy
69,995
+6,035
+9% +$24K ﹤0.01% 1446
2023
Q4 		$167K Buy
63,960
+3,295
+5% +$6.78K ﹤0.01% 1682
2023
Q3 		$113K Buy
60,665
+451
+0.7% +$860 ﹤0.01% 1611
2023
Q2 		$151K Buy
60,214
+11,844
+24% +$21.6K ﹤0.01% 1610
2023
Q1 		$84.6K Buy
48,370
+31,719
+190% +$86.5K ﹤0.01% 1620
2022
Q4 		$70.8K Sell
16,651
-274
-2% -$498 ﹤0.01% 1702
2022
Q3 		$20K Buy
+16,925
New +$19.1K ﹤0.01% 1716
2022
Q2 		– Sell
-15,054
Closed -$37K – 2088
2022
Q1 		$37K Sell
15,054
-4,464
-23% -$11.3K ﹤0.01% 2134
2021
Q4 		$52K Sell
19,518
-4,663
-19% -$22.4K ﹤0.01% 2280
2021
Q3 		$121K Buy
24,181
+877
+4% +$6.29K ﹤0.01% 1888
2021
Q2 		$174K Buy
23,304
+11,879
+104% +$77.9K ﹤0.01% 2182
2021
Q1 		$67K Sell
11,425
-1,271
-10% -$8.2K ﹤0.01% 2205
2020
Q4 		$60K Buy
+12,696
New +$53.8K ﹤0.01% 2034

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ProShare Advisors's SMMT Position: Q2 2026 in Review

ProShare Advisors reduced its Summit Therapeutics (SMMT) stake by 27% in Q2 2026, selling an estimated $164K and leaving 25,451 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #1288.

ProShare Advisors first reported a position in SMMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.3M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • ProShare Advisors held 25,451 shares of Summit Therapeutics worth $371K as of Q2 2026.
  • ProShare Advisors sold 9,235 Summit Therapeutics shares in Q2 2026, an estimated $164K.
  • Summit Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1288 holding.
  • ProShare Advisors first reported a position in Summit Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • ProShare Advisors's Summit Therapeutics position peaked at $1.3M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.